Oncology Peer Review On-The-Go: Molecular Profiling Practices in Pancreatic Adenocarcinoma

Podcast

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

In this week’s “Oncology Peer Review On-The-Go,” we discuss an article from the May issue of the journal ONCOLOGY® titled Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community Physicians. CancerNetwork® spoke with Christine Chung, DO, from the HCA Swedish Medical Center in Englewood, Colorado, about the molecular profiling patterns she and her colleagues observed in this retrospective review. The authors found that both academic and community physicians ordered profiling about 50% of the time, which was contrary to previous reports that suggest academic centers perform molecular profiling more often.

The perspective for this article comes from Roman Groisberg, MD, a medical oncologist and director of the Sarcoma Medical Oncology Program at the Rutgers Cancer Institute in New Brunswick, New Jersey. Groisberg discussed the role of profiling in pancreatic adenocarcinoma, his thoughts on the retrospective review, and the future of profiling for this cohort of patients.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Related Content